A Phase 3 interventional study of Placebo and Lebrikizumab in Atopic Dermatitis, sponsored by Eli Lilly and Company. Completed at 46 sites in 2 countries. Open to participants aged 12 Years and older. Per ClinicalTrials.gov, last updated 2026-10-16.
Sponsored by Eli Lilly and Company · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 24 studies testing lebrikizumab in Dermatitis, Atopic — 4 open to participants now, 7 under way, 4 of them phase 3. lebrikizumab · Dermatitis, Atopic.
Among the 24 studies testing lebrikizumab in Dermatitis, Atopic, this one is the 8th largest by enrollment, is one of 2 that started in 2024, is one of 17 in phase 3, and was the 18th registered.
1,594 studies on the registry are indexed under Dermatitis, Atopic; 287 are open to participants now.
Browse Dermatitis, Atopic studies →4 of the 24 studies testing lebrikizumab in Dermatitis, Atopic are open now, in 12 countries. Recruiting first, the newest first:
Eli Lilly and Company · Sites in United States, Argentina, Australia and 10 more countries
Ages 6 mo–18 yrs
Forefront Dermatology S.C · Sites in United States
Ages 12+
Almirall, S.A.
Ages 12+
University of California, San Francisco · Sites in United States
Ages 18+
By country, each count listing its studies:
lebrikizumab: first FDA approval 2024 (EBGLYSS), first EMA approval 2023. What it is approved for, and how studies give it, is on its page →
Of the 194 Dermatitis, Atopic studies recruiting now, 83 (43%) set no upper age limit and 95 (49%) stop at 75 or younger; 94 take children under 18; 51 take healthy volunteers.
This study: 12 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
24 studies; the count open now beside each. This study's row is marked.
First in 2015; this study’s year is marked. 2 started in 2024.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 301 is above the median of 82 across 1,248 interventional studies indexed under Dermatitis, Atopic.
Median enrollment 252 across the 24 interventional studies. Of the 17 that completed or were terminated, 13 (76%) have results posted.
This tab as a report to print or save as PDF → With an account.
21 of 24 have an industry lead sponsor. The 6 most frequent:
Eli Lilly and Company is the lead sponsor of 2,108 studies on the registry; 153 are open to participants now.
Of its 537 completed or terminated interventional studies of FDA-regulated products, 358 (67%) have results posted.
30 studies in Dermatitis, Atopic by Eli Lilly and Company: 1 open now, 2 under way, 2 of them phase 3. Of 28 finished, 25 (89%) have results posted.
Among the 30 studies in Dermatitis, Atopic by Eli Lilly and Company, this one is the 14th largest by enrollment, is one of 2 that started in 2024, is one of 21 in phase 3, and was the 28th registered.
Eli Lilly and Company’s Dermatitis, Atopic studies by the year they started, since 2013.
3 of the studies testing lebrikizumab in Dermatitis, Atopic that are under way reach primary completion within a year, 1 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06526182Phase 3Almirall, S.A.A Study of Lebrikizumab Treatment in Adults and Adolescents With Moderate-to-Severe Atopic Dermatitis | 2027-04-25 |
| NCT06906497Johann E Gudjonsson MD PhDLebrikizumab in Moderate-to-severe Atopic Dermatitis | 2027-07 |
| NCT07856134Forefront Dermatology S.CAD Treatment Optimization With Ebglyss in Real-World Practice: A Multicenter Study of Patient-Centered Outcomes | 2027-08-31 |
Add all 3 to your calendar (.ics) → With an account.
Among the 24 studies testing lebrikizumab in Dermatitis, Atopic, from their registry updates:
Among Eli Lilly and Company’s 30 in Dermatitis, Atopic:
This tab as a report to print or save as PDF → With an account.
The main purpose of this study is to evaluate the efficacy and safety of lebrikizumab with/without Topical Corticosteroid Treatment in Participants with Moderate-to-Severe Atopic Dermatitis. The study will last approximately 62 weeks.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Have a documented history provided by a physician and/or investigator of inadequate response to existing topical medications within 6 months preceding screening as defined by at least 1 of the following:
Exclusion Criteria:
Have a diagnosis or history of malignant disease within 5 years before screening, with the following exceptions:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Corticosteroids (steroids)
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis B tests
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis C tests
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HIV
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Metastases
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Participants received Placebo injection subcutaneously administered every 2 weeks (Q2W) in combination with topical corticosteroid (TCS) up to Week 16.
Drug: Placebo · Drug: Topical Corticosteroid
Participant received 250 mg (milligrams) Lebrikizumab injection subcutaneously administered Q2W in combination with TCS up to Week 16.
Drug: Lebrikizumab
Participant received 250 mg Lebrikizumab injection subcutaneously administered Q2W up to Week 16.
Drug: Lebrikizumab
Participant received Placebo injection subcutaneously administered Q2W up to Week 16.
Drug: Placebo
Subcutaneous injection
Subcutaneous injection
Also known as: LY3650150
Topical Corticosteroid
Percentage of Participants Achieving Eczema Area and Severity Index (EASI)-75 (≥75% Reduction From Baseline in EASI Score) at Week 16 (Combo Cohort: Placebo + TCS Versus 250 mg Lebrikizumab + TCS; Mono Cohort: Placebo Versus 250 mg Lebrikizumab)
EASI assesses objective physician estimates of 2 dimensions of atopic dermatitis - disease extent and clinical signs, by scoring the extent of disease (percentage of skin affected: 0 = 0%; 1 = 1-9%; 2 = 10-29%; 3 = 30-49%; 4 = 50-69%; 5 = 70-89%; 6 = 90-100%) and the severity of 4 clinical signs (erythema, edema/papulation, excoriation, and lichenification) each on a scale of 0 to 3 (0 = none, absent; 1 = mild; 2 = moderate; 3 = severe) at 4 body sites (head and neck, trunk, upper limbs, and lower limbs). Half scores are allowed. The final EASI score will be obtained by weight-averaging these 4 scores and will range from 0 to 72. A higher score represents greater disease severity. The EASI-75 responder is defined as a participant who achieves a ≥ 75% reduction from baseline in the EASI score.
Time frame: Week 16
Percentage of Participants With a Response of Investigator Global Assessment (IGA) Score 0 or 1 and a Reduction of ≥2 Points From Baseline to Week 16 (Combo Cohort: Placebo + TCS Vs 250 mg Lebrikizumab + TCS; Mono Cohort: Placebo Vs 250 mg Lebrikizumab)
The IGA measures the investigator's global assessment of the participant's overall severity of their Atopic Dermatitis. The IGA is comprised of a 5-point numeric scale ranging from 0 (clear skin) to 4 (severe disease) and a score is selected using descriptors that best describe the overall appearance of the lesions at a given time point.
Time frame: Baseline, Week 16
Percentage of Participants Achieving Response of Eczema Area and Severity Index (EASI)-90 (≥90% Reduction From Baseline in EASI Score) at Week 16 (Combo Cohort: Placebo + TCS Vs 250 mg Lebrikizumab + TCS; Mono Cohort: Placebo Vs 250 mg Lebrikizumab)
EASI assesses objective physician estimates of 2 dimensions of atopic dermatitis - disease extent and clinical signs, by scoring the extent of disease (percentage of skin affected: 0 = 0%; 1 = 1-9%; 2 = 10-29%; 3 = 30-49%; 4 = 50-69%; 5 = 70-89%; 6 = 90-100%) and the severity of 4 clinical signs (erythema, edema/papulation, excoriation, and lichenification) each on a scale of 0 to 3 (0 = none, absent; 1 = mild; 2 = moderate; 3 = severe) at 4 body sites (head and neck, trunk, upper limbs, and lower limbs). Half scores are allowed. The final EASI score will be obtained by weight-averaging these 4 scores and will range from 0 to 72. A higher score represents greater disease severity. The EASI-90 responder is defined as a participant who achieves a ≥ 90% reduction from baseline in the EASI score.
Time frame: Week 16
Percentage of Participants Who Achieved a ≥4 Point Improvement in Itch Numerical Rating Scale (NRS) Score at Week 16 (Combo Cohort: Placebo + TCS Versus 250 mg Lebrikizumab + TCS; Mono Cohort: Placebo Versus 250 mg Lebrikizumab)
Percentage of Participants who Achieved a ≥4 Point improvement in Itch NRS Score at Week 16 is reported. The Itch NRS is a an 11-point scale used by participants to rate their worst itch severity over the past 24 hours with 0 indicating "No itch" and 10 indicating "Worst itch imaginable."
Time frame: Week 16
Percent Change From Baseline in Itch Numeric Rating Scale (NRS) (Combo Cohort: Placebo + TCS Versus 250 mg Lebrikizumab + TCS; Mono Cohort: Placebo Versus 250 mg Lebrikizumab)
The Itch NRS is a an 11-point scale used by participants to rate their worst itch severity over the past 24 hours with 0 indicating "No itch" and 10 indicating "Worst itch imaginable". LS mean was calculated using MMRM model which includes: treatment, baseline value, visit, the interaction of the baseline value-by-visit, the interaction of treatment by-visit, age group, baseline IGA score and country.
Time frame: Baseline, Week 16
Change From Baseline in Dermatology Life Quality Index (DLQI) Total Score (Combo Cohort: Placebo + TCS Versus 250 mg Lebrikizumab + TCS; Mono Cohort: Placebo Versus 250 mg Lebrikizumab)
The DLQI questionnaire is a 10-item, quality-of-life questionnaire (for participants \>=16 years) that covers 6 domains (symptoms and feelings, daily activities, leisure, work and school, personal relationships, treatment) to assess impact of skin disease on the quality of life of an affected person. The recall period of this scale is over the "last week." Response categories include "Not at all," "A little," "A lot," and "Very much," with corresponding scores of 0, 1, 2, and 3 respectively, and unanswered (or "not relevant") responses scored as 0. Questions are scored from 0 to 3, giving possible total score range from 0 (no impact of skin disease on quality of life) to 30 (maximum impact on quality of life). A high score is indicative of a poor quality of life. LS mean was calculated using MMRM model which includes :treatment, baseline value, visit, the interaction of the baseline value-by-visit, the interaction of treatment by-visit, age group, baseline IGA score and country.
Time frame: Baseline, Week 16
Percent Change From Baseline in Total Eczema Area and Severity Index (Combo Cohort: Placebo + TCS Versus 250 mg Lebrikizumab + TCS; Mono Cohort: Placebo Versus 250 mg Lebrikizumab)
EASI assesses objective physician estimates of 2 dimensions of atopic dermatitis - disease extent and clinical signs, by scoring the extent of disease (percentage of skin affected: 0 = 0%; 1 = 1-9%; 2 = 10-29%; 3 = 30-49%; 4 = 50-69%; 5 = 70-89%; 6 = 90-100%) and the severity of 4 clinical signs (erythema, edema/papulation, excoriation, and lichenification) each on a scale of 0 to 3 (0 = none, absent; 1 = mild; 2 = moderate; 3 = severe) at 4 body sites (head and neck, trunk, upper limbs, and lower limbs). Half scores are allowed. The final EASI score will be obtained by weight-averaging these 4 scores and will range from 0 to 72. A higher score represents greater disease severity.
Time frame: Baseline, Week 16
| Milestone | Combo Cohort: Placebo + TCS | Combo Cohort: 250 mg Lebrikizumab + TCS | Mono Cohort: Placebo | Mono Cohort: 250 mg Lebrikizumab |
|---|---|---|---|---|
| Started | 56 | 112 | 44 | 89 |
| Completed | 2 | 13 | 3 | 5 |
| Not completed | 54 | 99 | 41 | 84 |
| Withdrew: Withdrawal by parent/guardian | 0 | 1 | 1 | 0 |
| Withdrew: Withdrawal by subject | 5 | 15 | 2 | 5 |
| Withdrew: Lost to follow-up | 0 | 0 | 0 | 1 |
| Withdrew: Lack of efficacy | 0 | 1 | 1 | 1 |
| Withdrew: Adverse event | 2 | 2 | 2 | 2 |
| Withdrew: Other | 0 | 1 | 0 | 0 |
| Withdrew: Protocol deviation | 0 | 2 | 0 | 0 |
| Withdrew: Ongoing | 47 | 77 | 35 | 75 |
EASI assesses objective physician estimates of 2 dimensions of atopic dermatitis - disease extent and clinical signs, by scoring the extent of disease (percentage of skin affected: 0 = 0%; 1 = 1-9%; 2 = 10-29%; 3 = 30-49%; 4 = 50-69%; 5 = 70-89%; 6 = 90-100%) and the severity of 4 clinical signs (erythema, edema/papulation, excoriation, and lichenification) each on a scale of 0 to 3 (0 = none, absent; 1 = mild; 2 = moderate; 3 = severe) at 4 body sites (head and neck, trunk, upper limbs, and lower limbs). Half scores are allowed. The final EASI score will be obtained by weight-averaging these 4 scores and will range from 0 to 72. A higher score represents greater disease severity. The EASI-75 responder is defined as a participant who achieves a ≥ 75% reduction from baseline in the EASI score.
| percentage of participants | Combo Cohort: Placebo + TCS | Combo Cohort: 250 mg Lebrikizumab + TCS | Mono Cohort: Placebo | Mono Cohort: 250 mg Lebrikizumab |
|---|---|---|---|---|
| Percentage of Participants Achieving Eczema Area and Severity Index (EASI)-75 (≥75% Reduction From Baseline in EASI Score) at Week 16 (Combo Cohort: Placebo + TCS Versus 250 mg Lebrikizumab + TCS; Mono Cohort: Placebo Versus 250 mg Lebrikizumab) | 37.8 | 57.5 | 18.5 | 51.7 |
The IGA measures the investigator's global assessment of the participant's overall severity of their Atopic Dermatitis. The IGA is comprised of a 5-point numeric scale ranging from 0 (clear skin) to 4 (severe disease) and a score is selected using descriptors that best describe the overall appearance of the lesions at a given time point.
| percentage of participants | Combo Cohort: Placebo + TCS | Combo Cohort: 250 mg Lebrikizumab + TCS | Mono Cohort: Placebo | Mono Cohort: 250 mg Lebrikizumab |
|---|---|---|---|---|
| Percentage of Participants With a Response of Investigator Global Assessment (IGA) Score 0 or 1 and a Reduction of ≥2 Points From Baseline to Week 16 (Combo Cohort: Placebo + TCS Vs 250 mg Lebrikizumab + TCS; Mono Cohort: Placebo Vs 250 mg Lebrikizumab) | 17.2 | 25.0 | 7.1 | 27.0 |
EASI assesses objective physician estimates of 2 dimensions of atopic dermatitis - disease extent and clinical signs, by scoring the extent of disease (percentage of skin affected: 0 = 0%; 1 = 1-9%; 2 = 10-29%; 3 = 30-49%; 4 = 50-69%; 5 = 70-89%; 6 = 90-100%) and the severity of 4 clinical signs (erythema, edema/papulation, excoriation, and lichenification) each on a scale of 0 to 3 (0 = none, absent; 1 = mild; 2 = moderate; 3 = severe) at 4 body sites (head and neck, trunk, upper limbs, and lower limbs). Half scores are allowed. The final EASI score will be obtained by weight-averaging these 4 scores and will range from 0 to 72. A higher score represents greater disease severity. The EASI-90 responder is defined as a participant who achieves a ≥ 90% reduction from baseline in the EASI score.
| percentage of participants | Combo Cohort: Placebo + TCS | Combo Cohort: 250 mg Lebrikizumab + TCS | Mono Cohort: Placebo | Mono Cohort: 250 mg Lebrikizumab |
|---|---|---|---|---|
| Percentage of Participants Achieving Response of Eczema Area and Severity Index (EASI)-90 (≥90% Reduction From Baseline in EASI Score) at Week 16 (Combo Cohort: Placebo + TCS Vs 250 mg Lebrikizumab + TCS; Mono Cohort: Placebo Vs 250 mg Lebrikizumab) | 19.1 | 33.9 | 11.5 | 30.3 |
Percentage of Participants who Achieved a ≥4 Point improvement in Itch NRS Score at Week 16 is reported. The Itch NRS is a an 11-point scale used by participants to rate their worst itch severity over the past 24 hours with 0 indicating "No itch" and 10 indicating "Worst itch imaginable."
| percentage of participants | Combo Cohort: Placebo + TCS | Combo Cohort: 250 mg Lebrikizumab + TCS | Mono Cohort: Placebo | Mono Cohort: 250 mg Lebrikizumab |
|---|---|---|---|---|
| Percentage of Participants Who Achieved a ≥4 Point Improvement in Itch Numerical Rating Scale (NRS) Score at Week 16 (Combo Cohort: Placebo + TCS Versus 250 mg Lebrikizumab + TCS; Mono Cohort: Placebo Versus 250 mg Lebrikizumab) | 19.5 | 31.7 | 22.1 | 41.0 |
The Itch NRS is a an 11-point scale used by participants to rate their worst itch severity over the past 24 hours with 0 indicating "No itch" and 10 indicating "Worst itch imaginable". LS mean was calculated using MMRM model which includes: treatment, baseline value, visit, the interaction of the baseline value-by-visit, the interaction of treatment by-visit, age group, baseline IGA score and country.
| Percent change | Combo Cohort: Placebo + TCS | Combo Cohort: 250 mg Lebrikizumab + TCS | Mono Cohort: Placebo | Mono Cohort: 250 mg Lebrikizumab |
|---|---|---|---|---|
| Percent Change From Baseline in Itch Numeric Rating Scale (NRS) (Combo Cohort: Placebo + TCS Versus 250 mg Lebrikizumab + TCS; Mono Cohort: Placebo Versus 250 mg Lebrikizumab) | -29.40 ± 5.13 | -41.19 ± 3.60 | -19.57 ± 9.83 | -41.97 ± 6.65 |
The DLQI questionnaire is a 10-item, quality-of-life questionnaire (for participants \>=16 years) that covers 6 domains (symptoms and feelings, daily activities, leisure, work and school, personal relationships, treatment) to assess impact of skin disease on the quality of life of an affected person. The recall period of this scale is over the "last week." Response categories include "Not at all," "A little," "A lot," and "Very much," with corresponding scores of 0, 1, 2, and 3 respectively, and unanswered (or "not relevant") responses scored as 0. Questions are scored from 0 to 3, giving possible total score range from 0 (no impact of skin disease on quality of life) to 30 (maximum impact on quality of life). A high score is indicative of a poor quality of life. LS mean was calculated using MMRM model which includes :treatment, baseline value, visit, the interaction of the baseline value-by-visit, the interaction of treatment by-visit, age group, baseline IGA score and country.
| score on a scale | Combo Cohort: Placebo + TCS | Combo Cohort: 250 mg Lebrikizumab + TCS | Mono Cohort: Placebo | Mono Cohort: 250 mg Lebrikizumab |
|---|---|---|---|---|
| Change From Baseline in Dermatology Life Quality Index (DLQI) Total Score (Combo Cohort: Placebo + TCS Versus 250 mg Lebrikizumab + TCS; Mono Cohort: Placebo Versus 250 mg Lebrikizumab) | -4.45 ± 0.800 | -5.75 ± 0.563 | -2.92 ± 0.926 | -6.01 ± 0.704 |
EASI assesses objective physician estimates of 2 dimensions of atopic dermatitis - disease extent and clinical signs, by scoring the extent of disease (percentage of skin affected: 0 = 0%; 1 = 1-9%; 2 = 10-29%; 3 = 30-49%; 4 = 50-69%; 5 = 70-89%; 6 = 90-100%) and the severity of 4 clinical signs (erythema, edema/papulation, excoriation, and lichenification) each on a scale of 0 to 3 (0 = none, absent; 1 = mild; 2 = moderate; 3 = severe) at 4 body sites (head and neck, trunk, upper limbs, and lower limbs). Half scores are allowed. The final EASI score will be obtained by weight-averaging these 4 scores and will range from 0 to 72. A higher score represents greater disease severity.
| Percent change | Combo Cohort: Placebo + TCS | Combo Cohort: 250 mg Lebrikizumab + TCS | Mono Cohort: Placebo | Mono Cohort: 250 mg Lebrikizumab |
|---|---|---|---|---|
| Percent Change From Baseline in Total Eczema Area and Severity Index (Combo Cohort: Placebo + TCS Versus 250 mg Lebrikizumab + TCS; Mono Cohort: Placebo Versus 250 mg Lebrikizumab) | -58.75 ± 5.121 | -69.44 ± 3.825 | -30.25 ± 6.373 | -60.12 ± 5.039 |
Collected over Baseline up to week 16. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Combo Cohort: Placebo + TCS | 0/56 (0%) | 1/56 (1.8%) | 26/56 (46.4%) |
| Combo Cohort: 250 mg Lebrikizumab + TCS | 0/112 (0%) | 3/112 (2.7%) | 31/112 (27.7%) |
| Mono Cohort: Placebo | 0/44 (0%) | 1/44 (2.3%) | 14/44 (31.8%) |
| Mono Cohort: 250 mg Lebrikizumab | 0/89 (0%) | 0/89 (0%) | 31/89 (34.8%) |
| Event | Combo Cohort: Placebo + TCS | Combo Cohort: 250 mg Lebrikizumab + TCS | Mono Cohort: Placebo | Mono Cohort: 250 mg Lebrikizumab |
|---|---|---|---|---|
| Humerus fractureInjury, poisoning and procedural complications | 0/56 | 0/112 | 1/44 | 0/89 |
| Herpes zosterInfections and infestations | 1/56 | 0/112 | 0/44 | 0/89 |
| AppendicitisInfections and infestations | 0/56 | 1/112 | 0/44 | 0/89 |
| Post herpetic neuralgiaNervous system disorders | 0/56 | 1/112 | 0/44 | 0/89 |
| Pleural effusionRespiratory, thoracic and mediastinal disorders | 0/56 | 1/112 | 0/44 | 0/89 |
| PleurisyRespiratory, thoracic and mediastinal disorders | 0/56 | 1/112 | 0/44 | 0/89 |
| Event | Combo Cohort: Placebo + TCS | Combo Cohort: 250 mg Lebrikizumab + TCS | Mono Cohort: Placebo | Mono Cohort: 250 mg Lebrikizumab |
|---|---|---|---|---|
| Upper respiratory tract infectionInfections and infestations | 9/56 | 9/112 | 6/44 | 5/89 |
| Alanine aminotransferase increasedInvestigations | 3/56 | 5/112 | 4/44 | 5/89 |
| Blood creatine phosphokinase increasedInvestigations | 4/56 | 2/112 | 1/44 | 5/89 |
| Aspartate aminotransferase increasedInvestigations | 3/56 | 4/112 | 3/44 | 2/89 |
| ConjunctivitisInfections and infestations | 3/56 | 6/112 | 0/44 | 6/89 |
| Injection site reactionGeneral disorders | 2/56 | 3/112 | 0/44 | 5/89 |
| Skin infectionInfections and infestations | 3/56 | 1/112 | 0/44 | 0/89 |
| Blood lactate dehydrogenase increasedInvestigations | 3/56 | 1/112 | 2/44 | 3/89 |
| HyperuricaemiaMetabolism and nutrition disorders | 3/56 | 6/112 | 2/44 | 3/89 |
All Randomized participants.
| Age, Categorical(Participants) | Combo Cohort: Placebo + TCS | Combo Cohort: 250 mg Lebrikizumab + TCS | Mono Cohort: Placebo | Mono Cohort: 250 mg Lebrikizumab | Total |
|---|---|---|---|---|---|
| <=18 years | 12 | 24 | 7 | 14 | 57 |
| Between 18 and 65 years | 38 | 76 | 32 | 72 | 218 |
| >=65 years | 6 | 12 | 5 | 3 | 26 |
| Sex: Female, Male(Participants) | Combo Cohort: Placebo + TCS | Combo Cohort: 250 mg Lebrikizumab + TCS | Mono Cohort: Placebo | Mono Cohort: 250 mg Lebrikizumab | Total |
|---|---|---|---|---|---|
| Female | 17 | 36 | 20 | 28 | 101 |
| Male | 39 | 76 | 24 | 61 | 200 |
| Ethnicity (NIH/OMB)(Participants) | Combo Cohort: Placebo + TCS | Combo Cohort: 250 mg Lebrikizumab + TCS | Mono Cohort: Placebo | Mono Cohort: 250 mg Lebrikizumab | Total |
|---|---|---|---|---|---|
| Hispanic or Latino | 0 | 0 | 0 | 0 | 0 |
| Not Hispanic or Latino | 47 | 99 | 39 | 85 | 270 |
| Unknown or Not Reported | 9 | 13 | 5 | 4 | 31 |
| Race (NIH/OMB)(Participants) | Combo Cohort: Placebo + TCS | Combo Cohort: 250 mg Lebrikizumab + TCS | Mono Cohort: Placebo | Mono Cohort: 250 mg Lebrikizumab | Total |
|---|---|---|---|---|---|
| American Indian or Alaska Native | 0 | 0 | 0 | 0 | 0 |
| Asian | 56 | 112 | 44 | 89 | 301 |
| Native Hawaiian or Other Pacific Islander | 0 | 0 | 0 | 0 | 0 |
| Black or African American | 0 | 0 | 0 | 0 | 0 |
| White | 0 | 0 | 0 | 0 | 0 |
| More than one race | 0 | 0 | 0 | 0 | 0 |
| Unknown or Not Reported | 0 | 0 | 0 | 0 | 0 |
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: Yes — Anonymized individual patient level data will be provided in a secure access environment upon approval of a research proposal and a signed data sharing agreement.
Supporting information: Study protocol, Statistical analysis plan, Clinical study report
Time frame: Data are available 6 months after the primary publication and approval of the indication studied in the US and European Union (EU), whichever is later. Data will be indefinitely available for requesting.
Access criteria: A research proposal must be approved by an independent review panel and researchers must sign a data sharing agreement
Data sharing details ↗ · vivli.org
Ran from Apr 2024 to primary completion in Sep 2025, 17 months.
Results were first posted in Oct 2026, 1 year after primary completion.
Of 150 industry-sponsored phase 3 interventional studies under Dermatitis, Atopic, half reached primary completion within 18 months of starting (the median), counting those still running; a quarter within 13 and three quarters within 28. This study's 17 months is close to that.
Counting every sponsor, half of 157 studies reached it within 18 months; a quarter within 13 and three quarters within 28.
Completion moved once since we started tracking on Sep 25, 2026: Aug 2026 → Jul 2026, on Oct 16, 2026.
Earlier changes are on the record history on ClinicalTrials.gov ↗
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
This study is completed, as verified in Sep 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Lebrikizumab